Understand how the various components of the financial statements are impacted by a company's investments in marketable ...
Hosted on MSN1mon
Arbutus expects to significantly reduce its net cash burn in 2025The company had cash, cash equivalents and investments in marketable securities ... the imdusiran Phase 2b clinical trial. With its current cash balance and anticipated 2025 net cash burn, the ...
Q3 2024 Management View CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational ...
First subjects dosed in a Phase 2 trial of VTX3232 in participants ... cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 (unaudited) expected to fund operations ...
with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson's disease expected in H1 2025 Cash, cash equivalents and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback